CBL-B inhibitor piperidine compounds for cancer vaccine combinations
Summary
The European Patent Office published patent application EP3953346A1 by Nurix Therapeutics covering 3-substituted piperidine compounds as CBL-B inhibitors for combination therapy with cancer vaccines and oncolytic viruses. The patent application includes therapeutic compounds classified under A61P 35/00 (antineoplastic agents) and A61P 37/00 (immunomodulators), covering methods of treating cancer using the disclosed compounds.
What changed
The European Patent Office published EP3953346A1, a patent application by Nurix Therapeutics for 3-substituted piperidine compounds inhibiting CBL-B, an enzyme relevant to immune response modulation. The application covers methods of treating cancer by administering the disclosed compounds in combination with cancer vaccines and/or oncolytic viruses.
Pharmaceutical companies developing cancer immunotherapies, particularly those working on checkpoint inhibitors or cancer vaccine combinations, should monitor this patent landscape. The patent's broad claims covering CBL-B inhibitors in combination with cancer vaccines may affect freedom-to-operate considerations for competing therapeutic approaches.
What to do next
- Monitor for updates
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS
Publication EP3953346A1 Kind: A1 Apr 01, 2026
Applicants
Nurix Therapeutics, Inc.
Inventors
SANDS, Arthur T., BENCE, Neil F., ZAPF, Christoph W., COHEN, Frederick, WANG, Chenbo, CUMMINS, Thomas, TANAKA, Hiroko, SHUNATONA, Hunter, CARDOZO, Mario, WEISS, Dahlia, GOSLING, Jennifa
IPC Classifications
C07D 401/14 20060101AFI20201016BHEP C07D 405/14 20060101ALI20201016BHEP C07D 471/04 20060101ALI20201016BHEP C07D 491/107 20060101ALI20201016BHEP A61P 35/00 20060101ALI20201016BHEP A61P 37/00 20060101ALI20201016BHEP A61K 31/454 20060101ALI20201016BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.